Setmelanotide Adverse Events: What Studies Report

Setmelanotide is an injectable melanocortin-4 receptor (MC4R) agonist that has been studied in rare genetic and acquired forms of obesity involving the MC4R pathway. Because the melanocortin system also acts on receptors outside the hypothalamus, the adverse-event profile reported in trials has been dominated by a small, recurring set of events rather than by rare, scattered findings. This page summarises what published trials and reviews reported. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine, a symptom, or a treatment decision.

Where the safety data come from

The published safety record for setmelanotide comes from a handful of small, mostly open-label trials in rare-disease populations. Single-arm, open-label phase 3 trials examined the efficacy and safety of setmelanotide in individuals with severe obesity due to proopiomelanocortin (POMC) or leptin receptor (LEPR) deficiency (PMID 33137293). A multicentre, randomised, double-blind, placebo-controlled phase 3 trial with an open-label period assessed the drug in patients with Bardet-Biedl syndrome and Alström syndrome (PMID 36356613). The VENTURE trial, a one-year, open-label, multicentre phase 3 study, extended evaluation to children aged 2-5 years with rare MC4R pathway-associated obesity (PMID 39549719). A phase 2, open-label, multicentre trial evaluated setmelanotide in acquired hypothalamic obesity (PMID 38697184), and a subsequent randomised trial in the same population was reported in 2026 (PMID 42418774).

Two features of that evidence base shape every statement below. First, the trials enrolled dozens rather than thousands of participants, so uncommon events may simply not have appeared. Second, most reported follow-up spanned weeks to about a year, so multi-year safety was not characterised in these publications.

Skin Hyperpigmentation: What Studies Report

Skin darkening was among the most consistently reported events across trials. In the POMC and LEPR deficiency phase 3 trials, researchers listed skin hyperpigmentation among the most frequent adverse events recorded during treatment (PMID 33137293). The randomised trial in Bardet-Biedl and Alström syndromes likewise reported skin hyperpigmentation among the most common adverse events in treated participants (PMID 36356613), and the VENTURE trial in children aged 2-5 years reported skin hyperpigmentation among the adverse events observed over one year (PMID 39549719).

Reviews have framed this as a mechanism-linked observation rather than an unexpected one: a 2023 review of the central melanocortin system as a therapeutic target discussed pigmentary effects among the consequences of pharmacologically activating melanocortin receptors (PMID 37365323). A 2024 review of setmelanotide in severe obesity due to hypothalamic dysfunction also described pigmentation changes as a recognised feature of the drug's reported tolerability profile (PMID 39526054).

Darkening of naevi and pigmented lesions

Published trial reports grouped generalised skin darkening and changes in pigmented areas under hyperpigmentation terms rather than reporting them as separate outcome categories (PMID 33137293). Because the trials were small and short, they were not designed to quantify any longer-term dermatological consequence of sustained pigmentary change (PMID 36356613).

Injection-Site Reactions: What Studies Report

Setmelanotide was administered by subcutaneous injection in the published trials, and local reactions were among the events researchers most often recorded. The POMC and LEPR deficiency trials reported injection-site reactions among the most common adverse events (PMID 33137293), and the Bardet-Biedl and Alström syndrome trial reported injection-site erythema among frequently occurring events during the treatment period (PMID 36356613). These were described as part of the overall adverse-event tally rather than as events that dominated study withdrawal.

Gastrointestinal Events: What Studies Report

Nausea and vomiting recurred across populations. In the phase 2 trial in acquired hypothalamic obesity, researchers reported nausea and vomiting among the most common treatment-emergent adverse events alongside skin hyperpigmentation (PMID 38697184). Nausea also appeared among the most frequent events in the Bardet-Biedl and Alström syndrome trial (PMID 36356613) and in the POMC and LEPR deficiency trials (PMID 33137293). In the youngest cohort studied, the VENTURE trial reported gastrointestinal events including vomiting among adverse events observed over the one-year period (PMID 39549719).

Sexual and Reproductive-Tract Events: What Studies Report

Melanocortin agonism has pharmacological effects beyond appetite regulation. In the POMC and LEPR deficiency phase 3 trials, spontaneous penile erection was among the adverse events recorded in male participants (PMID 33137293). The 2023 review of the central melanocortin system discussed the breadth of physiological systems influenced by melanocortin receptor activation, which provides context for why such events were tracked (PMID 37365323).

Adverse Events in Children Aged 2-5 Years: What Studies Report

VENTURE was the trial that extended evaluation into early childhood. Over one year of open-label treatment in children aged 2-5 years with rare MC4R pathway-associated obesity, researchers reported adverse events including skin hyperpigmentation and gastrointestinal symptoms such as vomiting (PMID 39549719). Broader reviews of pharmacological management of paediatric obesity have placed setmelanotide within a narrow group of agents studied specifically in genetically defined obesity, noting that the paediatric evidence base is small relative to that for more widely used weight-management drugs (PMID 38321079). A 2026 review of childhood obesity medications and surgeries similarly situated setmelanotide among targeted options with limited long-term paediatric follow-up (PMID 41986930).

Acquired Hypothalamic Obesity Trials: What Studies Report

Hypothalamic damage after craniopharyngioma or other suprasellar tumours produces a distinct obesity phenotype. The phase 2, open-label, multicentre trial in acquired hypothalamic obesity reported nausea, vomiting, and skin hyperpigmentation among the most common treatment-emergent adverse events (PMID 38697184). A later randomised evaluation of setmelanotide in acquired hypothalamic obesity was published in 2026 and extended the trial evidence in this population beyond the open-label phase 2 setting (PMID 42418774). A narrative review of management after childhood-onset craniopharyngioma described the difficulty of treating this form of obesity and the limited number of pharmacological options with trial support (PMID 40426846).

Reported events by study population

Respiratory and Other Organ Systems: What Studies Report

Respiratory safety has become a general question across weight-loss pharmacotherapy. A 2026 systematic review and meta-analysis examined respiratory adverse events associated with weight-loss drugs as a class (PMID 42479131). That analysis addressed the weight-loss drug literature broadly rather than establishing a setmelanotide-specific respiratory signal, and the setmelanotide trials summarised above did not report respiratory events among their most frequent findings (PMID 36356613).

How the setmelanotide safety literature differs from other weight-loss drug literature

Comparative reviews of commonly studied weight-management agents have focused on semaglutide, liraglutide, orlistat, and phentermine, and did not include setmelanotide within that comparison set (PMID 40206909). That difference matters for interpretation: the adverse-event profile reported for setmelanotide came from small rare-disease trials, whereas the profiles of incretin-based and older agents were derived from much larger populations (PMID 38321079). Cross-drug comparisons of tolerability were therefore not supported by the trials described here.

What the published record does not establish

• Long-term safety. Reported follow-up in the trials summarised here spanned weeks to about one year, so multi-year outcomes were not characterised (PMID 39549719).
• Rare events. Trial sample sizes in rare-disease populations were small, which limits detection of uncommon adverse events (PMID 33137293).
• Use outside studied populations. The published trials enrolled genetically or clinically defined groups such as POMC and LEPR deficiency, Bardet-Biedl and Alström syndromes, and acquired hypothalamic obesity; safety in common polygenic obesity was not the subject of those reports (PMID 36356613, PMID 38697184).
• Pregnancy and lactation. The trials summarised here did not report on these settings (PMID 39526054).

Regulatory context

Setmelanotide is a prescription product authorised in the United States and Europe for specific rare, genetically confirmed forms of obesity, and reviews have described its position as a targeted therapy rather than a general weight-management drug (PMID 39526054). Reviews of paediatric obesity pharmacotherapy have noted that genetic confirmation defines the populations in which the agent was studied (PMID 38321079). Any question about eligibility, monitoring, or adverse events belongs with a prescribing clinician.

References

• Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials (The Lancet Diabetes & Endocrinology, 2020)
• Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period (The Lancet Diabetes & Endocrinology, 2022)
• Targeting the central melanocortin system for the treatment of metabolic disorders (Nature Reviews Endocrinology, 2023)
• Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial (The Lancet Diabetes & Endocrinology, 2024)
• Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of Severe Obesity Due to Hypothalamic Dysfunction (touchREVIEWS in Endocrinology, 2024)
• Setmelanotide in patients aged 2-5 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial (The Lancet Diabetes & Endocrinology, 2025)
• Current and future state of pharmacological management of pediatric obesity (International Journal of Obesity, 2025)
• Management of Acquired Hypothalamic Obesity After Childhood-Onset Craniopharyngioma - A Narrative Review (Biomedicines, 2025)
• Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review (Cureus, 2025)
• Setmelanotide for the Treatment of Acquired Hypothalamic Obesity (The New England Journal of Medicine, 2026)
• Childhood Obesity, Medications, and Surgeries (Cardiology in Review, 2026)
• Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis (Annals of the American Thoracic Society, 2026)